Literature DB >> 9516910

A prospective study of K-ras mutations in the plasma of pancreatic cancer patients.

H E Mulcahy1, J Lyautey, C Lederrey, X qi Chen, P Anker, E M Alstead, A Ballinger, M J Farthing, M Stroun.   

Abstract

K-ras mutations are frequently found in primary pancreatic adenocarcinomas. In this prospective study, we looked for K-ras mutations in the plasma of patients with pancreatic cancer. We isolated plasma DNA from 21 pancreatic cancer patients using a simple and rapid extraction technique and detected K-ras alterations with a PCR assay and subsequent product sequencing. Patients were followed up to determine their clinical outcome. We found K-ras mutations in the plasma of 17 patients (81%). In cases in which both plasma and pancreatic tissue were available, DNA mutations were similar in corresponding plasma and tissue samples. Plasma DNA alterations were found 5-14 months before clinical diagnosis in four patients. Mutant DNA was not found in the plasma of two patients with chronic pancreatitis or in five healthy controls. Our results indicate that K-ras mutations are often found in DNA isolated from the plasma of pancreatic cancer patients and that a noninvasive plasma-based assay may provide qualitative diagnostic information to clinicians in the future. Larger studies are required to further assess the relevance of our findings to clinical practice.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9516910

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  37 in total

1.  Selective 'stencil'-aided pre-PCR cleavage of wild-type sequences as a novel approach to detection of mutant K-RAS.

Authors:  A V Lichtenstein; O I Serdjuk; T I Sukhova; H S Melkonyan; S R Umansky
Journal:  Nucleic Acids Res       Date:  2001-09-01       Impact factor: 16.971

2.  Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group.

Authors:  M Porta; N Malats; L Guarner; A Carrato; J Rifà; A Salas; J M Corominas; M Andreu; F X Real
Journal:  J Epidemiol Community Health       Date:  1999-11       Impact factor: 3.710

Review 3.  Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer.

Authors:  Francesca Riva; Oleksii I Dronov; Dmytro I Khomenko; Florence Huguet; Christophe Louvet; Pascale Mariani; Marc-Henri Stern; Olivier Lantz; Charlotte Proudhon; Jean-Yves Pierga; Francois-Clement Bidard
Journal:  Mol Oncol       Date:  2016-01-22       Impact factor: 6.603

Review 4.  Identifying molecular markers for the early detection of pancreatic neoplasia.

Authors:  Michael Goggins
Journal:  Semin Oncol       Date:  2007-08       Impact factor: 4.929

5.  Plasma DNA restoration for PCR applications.

Authors:  Y R Arias; E F Carrillo; F A Aristizábal
Journal:  J Clin Pathol       Date:  2007-08       Impact factor: 3.411

6.  Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients.

Authors:  Thomas E Liggett; Anatoliy A Melnikov; Jeffrey R Marks; Victor V Levenson
Journal:  Int J Cancer       Date:  2010-04-05       Impact factor: 7.396

7.  Histone deacetylation, as opposed to promoter methylation, results in epigenetic BIM silencing and resistance to EGFR TKI in NSCLC.

Authors:  Mingchuan Zhao; Yishi Zhang; Jiayu Li; Xuefei Li; Ningning Cheng; Qi Wang; Weijing Cai; Chao Zhao; Yayi He; Jianhua Chang; Caicun Zhou
Journal:  Oncol Lett       Date:  2017-11-14       Impact factor: 2.967

Review 8.  Pancreatic cancer and the FAMMM syndrome.

Authors:  Henry T Lynch; Ramon M Fusaro; Jane F Lynch; Randall Brand
Journal:  Fam Cancer       Date:  2007-11-09       Impact factor: 2.375

9.  Gene promoter hypermethylation in tumors and plasma of breast cancer patients.

Authors:  Young Kyung Bae; Young Ran Shim; Joon Hyuk Choi; Mi Jin Kim; Edward Gabrielson; Soo Jung Lee; Tae Yoon Hwang; Sei One Shin
Journal:  Cancer Res Treat       Date:  2005-08-31       Impact factor: 4.679

10.  Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer.

Authors:  Lei Zhang; James J Farrell; Hui Zhou; David Elashoff; David Akin; No-Hee Park; David Chia; David T Wong
Journal:  Gastroenterology       Date:  2009-11-18       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.